Posted: July 19, 2022 at 2:15 am
ERAS-601, a potential best-in-class SHP2 inhibitor, is being investigated alone and in combination in the ongoing FLAGSHP-1 Phase 1/1b trial
Read the rest here:
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination
Posted: July 19, 2022 at 2:15 am
Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent Group from Continued Violations of Federal Securities Laws and SEC and Florida Injunctions
See the article here:
AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid
Posted: July 19, 2022 at 2:15 am
- Global Phase 2 placebo-controlled trial enrolled twice as fast as the industry average, establishing a roadmap for future studies -
Posted: July 19, 2022 at 2:15 am
Acer has notified the FDA in the resubmission that the third-party contract packaging manufacturer is ready for inspection Acer has notified the FDA in the resubmission that the third-party contract packaging manufacturer is ready for inspection
Read more here:
Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs
Posted: July 19, 2022 at 2:15 am
-- Growth to benefit ABVC’s Vitargus medical device product --FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that, according to a recent study by Bosson Research, the global Retinal Surgical Instruments market, valued at USD 1.59 billion in 2021, is expected to reach USD2.46 billion by the end of 2028, growing at a CAGR of 6.08% between 2022 and 2028. This growth is expected to benefit ABVC’s development of its medical device, Vitargus, a gel-like substance that aims to help the eye maintain a round shape and keep the retina in place during and after retina re-attachment surgery.
See original here:
ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028
Posted: July 19, 2022 at 2:15 am
TORONTO, July 18, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), the premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at Clinical Operations in Oncology Trials East Coast 2022 July 19-20 in Boston, MA.
Link:
Axiom Exhibiting at Clinical Operations in Oncology Trials East Coast 2022
Posted: July 19, 2022 at 2:15 am
Company Announcement
Read the original here:
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the...
Posted: July 19, 2022 at 2:15 am
SAN FRANCISCO, July 18, 2022 (GLOBE NEWSWIRE) -- Cells for Cells ("C4C"), a clinical-stage biotech pioneering allogeneic stem cell and stem-cells-derived therapeutics for high-impact chronic diseases, announced a 6-month follow-up of the groundbreaking Clinical Data from the First-ever patient dosed with an exosome-produced therapy for osteoarthritis. The results were made public at an extracellular vesicles signature series during the ISCT annual meeting in San Francisco and the ISEV meeting in Lyon, France.
See the article here:
CELLS for CELLS treats the first-ever patient with an exosome-produced therapy for osteoarthritis
Posted: July 19, 2022 at 2:15 am
- The event will feature Prometheus management and key opinion leader presentations on PR600 target unveiling, scientific rationale, and corresponding therapeutic candidate, PRA052 -
More here:
Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022
Posted: July 19, 2022 at 2:15 am
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis
See more here:
Codexis Announces CEO Transition Effective August 9, 2022
